QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
OTCMKTS:TRLPF

Acerus Pharmaceuticals (TRLPF) Stock Forecast, Price & News

$0.22
0.00 (0.00%)
(As of 07/21/2023)
Compare
Today's Range
$0.22
$0.22
50-Day Range
$0.22
$0.22
52-Week Range
$0.08
$0.34
Volume
N/A
Average Volume
5,474 shs
Market Capitalization
$56.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TRLPF stock logo

About Acerus Pharmaceuticals (OTCMKTS:TRLPF) Stock

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

TRLPF Price History

TRLPF Stock News Headlines

Acerus Reports Second Quarter 2022 Financial Results
DOD Consultant's big 2024 prediction looks to be coming true
Earlier this year, a Department of Defense (DOD) consultant went public with a big prediction…About how a surprising 2024 event would dramatically affect you and your money. The most recent figures (published June 9th 2023) indicate he’s very likely to be right. Get the facts—learn how to prepare. Full analysis available free of charge here…
See More Headlines
Receive TRLPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TRLPF Company Calendar

Last Earnings
11/05/2018
Today
9/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:TRLPF
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Profitability

Net Income
$-18,790,000.00
Net Margins
-254.66%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.38 million

Miscellaneous

Free Float
N/A
Market Cap
$56.90 million
Optionable
Not Optionable
Beta
2.60
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Ms. Patricia Symmes
    Chief Operating Officer
  • Dr. Nathan Bryson
    Chief Scientific Officer
  • Mr. Philippe Savard
    VP, Gen. Counsel & Corp. Sec.
  • Mr. Edward Gudaitis
    Pres , CEO & Director
  • Mr. Robert M. Motz
    Chief Financial Officer













TRLPF Stock - Frequently Asked Questions

How have TRLPF shares performed in 2023?

Acerus Pharmaceuticals' stock was trading at $0.5579 at the beginning of the year. Since then, TRLPF stock has decreased by 60.6% and is now trading at $0.22.
View the best growth stocks for 2023 here
.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) announced its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative trailing twelve-month return on equity of 346.72% and a negative net margin of 254.66%.

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of TRLPF stock can currently be purchased for approximately $0.22.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals (OTCMKTS:TRLPF) has a market capitalization of $56.90 million and generates $7.38 million in revenue each year. The specialty pharmaceutical company earns $-18,790,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at ir@aceruspharma.com.

This page (OTCMKTS:TRLPF) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -